November 23, 2017
Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017
Media
November 22, 2017
First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer
November 22, 2017
Nordic Nanovector Capital Markets Day 2017
November 22, 2017
Nordic Nanovector ASA – Results for the Third Quarter 2017
November 20, 2017
Zubsolv® receives authorization for treatment of opioid dependence in Europe
November 16, 2017
Wilson Therapeutics to host conference call to provide third quarter 2017 business update
November 14, 2017
Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 14, 2017
Bonesupport – Cerament® G’s potential to prevent and manage biofilm-related bone infections highlighted in new high-profile publication
November 14, 2017
Targovax to present at upcoming investor conferences
November 13, 2017
Nexstim gains FDA clearance to commercialise its NBT® system in the US for the treatment of depression
